Epsilon Healthcare Limited (ASX:EPN): Manufacturing and Healthcare Operations in Focus

Aditi Sarkar

14 October 2026 08:18 PM AEDT

Epsilon Healthcare Limited (ASX:EPN): Manufacturing and Healthcare Operations in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Epsilon operates across pharmaceutical manufacturing, healthcare clinics and pharmacy services.
The March 2026 quarter recorded customer receipts of $3.14m.
The company reported quarterly revenue of $3.3m in its April 2026 activities update.
Manufacturing and pharmacy services contribute to the integrated healthcare model.
Cash flow, operating costs and the execution of manufacturing contracts remain key operating considerations.

Epsilon Healthcare Limited (ASX:EPN) operates a healthcare business spanning pharmaceutical contract development and manufacturing, clinical consultations and pharmacy services. The company’s 2026 operating disclosures describe how these activities are being developed as an integrated service platform, linking product production with healthcare delivery and patient supply. Its March-quarter update provides measurable information about receipts, revenue and expenditure alongside developments in manufacturing and pharmacy operations.

Manufacturing and Clinic Services Within One Platform

Through its pharmaceutical contract development and manufacturing activities, Epsilon Healthcare Limited (ASX:EPN) provides production services for pharmaceutical customers. Its broader operations also include clinics and pharmacy-related services. These businesses serve different functions: manufacturing involves the preparation and supply of products, while clinical consultations and pharmacy services relate to patient access and fulfilment. The distinction matters because progress in one division does not necessarily establish equivalent performance throughout the group.

Epsilon Healthcare Limited (ASX:EPN) described its aim of building an integrated healthcare and manufacturing platform in its April 2026 quarterly activities report. The same update identified additional business contracts and certifications as developments relevant to its commercial activities. Such disclosures describe operational initiatives, but they do not by themselves establish future production volumes, profitability or regulatory approvals for particular products.

March 2026 Receipts and Revenue

For the quarter ended 31 March 2026, Epsilon Healthcare Limited (ASX:EPN) reported customer receipts of $3.14m, an increase of 154% compared with the corresponding quarter. The company also reported group revenue of $3.3m for the period, equivalent to an average of approximately $1.1 million per month. Receipts and accounting revenue are different measures: customer receipts represent cash collected, whereas reported revenue follows the applicable recognition rules.

In the same quarterly update, the company reported that its contract development and manufacturing division recorded 149% year-on-year growth for the March quarter. Its pharmacy division was reported to have reached an annualised revenue rate of $2.3m. An annualised rate is calculated from a shorter operating period and should not be confused with revenue already earned over a full financial year.

Cash Movements and Operational Pressures

At 31 March 2026, Epsilon Healthcare Limited (ASX:EPN) reported cash of $503,000, compared with $242,000 at the preceding quarter-end. The company attributed part of the movement to $200,000 received through the conversion of options. Customer receipts rose from $2,891,000 in the preceding quarter to $3,140,000, while payments for cost of goods and operating costs increased from $1,904,000 to $2,217,000.

Labour payments were $712,000 in the March 2026 quarter compared with $1,066,000 in the preceding quarter. Administration and corporate costs were $100,000 compared with $397,000. These cash-flow components show that higher receipts occurred alongside changes in operating expenditure. Manufacturing utilisation, working-capital requirements, customer contracts and the timing of cash collections are relevant when assessing how the group’s activities translate into available cash.

Key Insights

Epsilon Healthcare Limited (ASX:EPN) combines pharmaceutical manufacturing with clinical and pharmacy operations. Its March 2026 update showed increases in customer receipts and disclosed specific changes in operating payments. The relationship between service delivery, manufacturing activity and cash generation remains central to understanding the business. Reported annualised rates and quarterly movements should be distinguished from audited full-year outcomes.

FAQs

Q: What does Epsilon Healthcare Limited do?

A:It operates pharmaceutical contract development and manufacturing, healthcare clinics and pharmacy services.

Q: What were customer receipts in the March 2026 quarter?

A:The company reported customer receipts of $3.14m.

Q: How much group revenue did it report for that quarter?

A:Epsilon reported $3.3m in quarterly group revenue.

Q: What was the quarter-end cash balance?

A:Cash on hand was $503,000 at 31 March 2026.

Q: Why are receipts and revenue presented separately?

A:Receipts measure cash collected, while revenue is recognised under accounting rules.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.